Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Holdings Raised by Captrust Financial Advisors

Captrust Financial Advisors grew its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 47.0% during the third quarter, HoldingsChannel.com reports. The firm owned 8,050 shares of the biopharmaceutical company’s stock after purchasing an additional 2,572 shares during the period. Captrust Financial Advisors’ holdings in Intra-Cellular Therapies were worth $589,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Perceptive Advisors LLC boosted its position in Intra-Cellular Therapies by 62.6% during the 2nd quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company’s stock valued at $117,557,000 after purchasing an additional 661,052 shares during the period. Millennium Management LLC lifted its stake in Intra-Cellular Therapies by 214.5% in the second quarter. Millennium Management LLC now owns 889,102 shares of the biopharmaceutical company’s stock valued at $60,895,000 after buying an additional 606,358 shares during the last quarter. Avoro Capital Advisors LLC boosted its holdings in shares of Intra-Cellular Therapies by 21.2% during the second quarter. Avoro Capital Advisors LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock valued at $205,470,000 after acquiring an additional 525,000 shares during the period. Marshall Wace LLP bought a new position in shares of Intra-Cellular Therapies during the second quarter worth about $34,178,000. Finally, Hood River Capital Management LLC acquired a new stake in shares of Intra-Cellular Therapies in the 2nd quarter worth about $33,390,000. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. The trade was a 4.55 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, President Michael Halstead sold 22,869 shares of Intra-Cellular Therapies stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total value of $2,038,085.28. The disclosure for this sale can be found here. 2.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on ITCI shares. Piper Sandler upgraded Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $68.00 to $92.00 in a research report on Friday, September 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, October 30th. Morgan Stanley raised their target price on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Royal Bank of Canada upped their price target on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an “outperform” rating in a research note on Friday, October 4th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a report on Monday, November 4th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $97.23.

Intra-Cellular Therapies Stock Performance

ITCI opened at $83.88 on Thursday. The firm has a market cap of $8.89 billion, a price-to-earnings ratio of -96.41 and a beta of 0.95. The firm’s 50-day simple moving average is $82.01 and its 200-day simple moving average is $76.52. Intra-Cellular Therapies, Inc. has a twelve month low of $58.92 and a twelve month high of $93.45.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The company had revenue of $175.40 million for the quarter, compared to analyst estimates of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. Intra-Cellular Therapies’s revenue for the quarter was up 39.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.25) earnings per share. As a group, sell-side analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.